Exponent, Inc. (EXPO)
NEUTRALFundamental
65
Price
$69.92
Market Cap
$3.39B
Part 1 · What the company is worth
Overview
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$632M
Trailing 12 months (through 7/3/2026)
Net Income
$112M
Trailing 12 months (through 7/3/2026)
Free Cash Flow
$122M
Total Equity
$390M
Total Liabilities
$387M
Current Ratio
1.98
Interest Coverage
-
Debt/EBITDA
0.62
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$63.65
Current Price
$69.92
Margin of Safety
-9.9%
Fair Value Range
$45.42 - $81.89
Estimation Methods
Valuation Metrics
P/E Ratio
31.88
ROE
27.2%
P/B Ratio
11.66
P/FCF
31.00
Gross Margin
-
ROIC
20.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
20.4%
WACC
8.1%
ROIC − WACC
+12.3 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (18)
- EPS shows upward trend
- Price CAGR 8.82%
- ROIC 20.4%
- Debt/Equity ratio
- Operating Margin 20.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 27.9%
- Revenue Growth 5Y 7.8%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 4.3%
- Earnings Quality (OCF/NI) 1.06
- Share Dilution -0.9%
- Piotroski F-Score 5/9
Failed (7)
- EPS CAGR 2.16%
- P/FCF 31.00
- P/B Ratio 11.66
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 4.90
- Net Margin Trend 17.7% vs 18.3%
Unavailable (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Catherine Ford Corrigan P.E., Ph.D. | CEO & Director | 56 |
| Mr. Richard L. Schlenker Jr. | Executive VP, Corporate Secretary & Director | 59 |
| Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D. | Group Vice President | 56 |
| Dr. Joseph Rakow Ph.D. | Group Vice President | 48 |
| Dr. Joseph Sala Ph.D. | Group Vice President | 48 |
| Dr. John D. Pye P.E., Ph.D. | President | 54 |
| Dr. Bernard Ross P.E., Ph.D. | Co-Founder & Principal Engineer | - |
| Mr. Eric R. Anderson | Chief Financial Officer | 50 |
| Ms. Gina Flynn | VP of Legal & General Counsel | - |
| Mr. Brian Kundert | Chief Human Resources Officer | 50 |
Audit Risk
9
Board Risk
2
Compensation Risk
4
Shareholder Rights Risk
2
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for EXPO, sourced from Markets Gazette.